Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial.

AIDS (London, England)

Volumn 23, Issue 16, 2009, Pages 2222-2223

  Read, Tim R H ^a   Carey, Dianne ^b   Mallon, Patrick ^b   Mijch, Anne ^b   Goodall, Ruth ^b   Hudson, Fleur ^b   Wand, Handan ^b   Emery, Sean ^b  

^a MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; EFAVIRENZ;

ARTICLE; BLOOD; CASE CONTROL STUDY; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG MONITORING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK FACTOR;

ANTI-HIV AGENTS; BENZOXAZINES; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM DISEASES; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; SLEEP INITIATION AND MAINTENANCE DISORDERS;

MLCS; MLOWN;

EID: 79952115077     PISSN: None     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/qad.0b013e32832e95f8     Document Type: Article

References (0)